Supplemental Table 1. Oncological endpoints by BCG treatment dose

|  |  |  |
| --- | --- | --- |
| **Endpoint** | **Treatment cohort** | **Time point mean % (95% CI)** |
|  |  | 6 m | 12m | 24m | 36m | 48m | 60m |
| Recurrence free rate | RD | 81 (72-87) | 71(62-78)  | 61 (51-69) | 56 (46-69) | 54 (44-63) | 50 (40-59) |
| FD | 93 (84-97) | 87 (78-93) | 82 (71-89) | 82 (71-89) | 78 (65-87) | 78 (65-87) |
| HG-recurrence free rate | RD | 84 (77-90) | 75 (66-82) | 69 (59-77) | 66 (56-74) | 65 (55-73) | 61 (51-70) |
| FD | 95 (88-98) | 91 (83-96) | 87 (78-93) | 87 (78-93) | 87 (78-93) | 87 (78-93) |
| Progression free rate | RD | 97 (92-99) | 96 (91-99) | 96 (90-98) | 95 (88-98) | 93 (87-97) | 91 (84-95) |
| FD | 98 (91-99) | 98 (91-99) | 98 (91-99) | 98 (91-99) | 98 (91-99) | 98 (91-99) |
| OS  | RD | 100 | 96 (90-98) | 92 (85-96) | 88 (80-93) | 86 (78-91) | 84 (76-90) |
| FD | 99 (92-100) | 99 (92-100) | 97 (90-99) | 94 (84-98) | 94 (84-98) | 94 (84-98) |